Inna D. Amelina
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Inna D. Amelina has a total of 30 co-authors. Here are the top co-authors by number of shared publications:
- Lev N. Shevkunov
N.N. Petrov National Medical Research Center of Oncology
4 shared publications - Aleksei Mikhailovich Karachun
Национальный медицинский исследовательский центр онкологии им. Н.Н. Петрова Министерства здравоохранения Российской Федерации
3 shared publications - Anna S. Artemyeva
N. N. Petrov National Medical Research Center of Oncology, Ministry of Health of Russia
2 shared publications - Denis V. Nesterov
Federal State Budgetary Institution "N.N. Petrov National Medical Research Center of Oncology" of the Ministry of Health of the Russian Federation, St. Petersburg, Russia
2 shared publications - Sergey Sergeevich Bagnenko
N. N. Petrov National Medical Research Center of Oncology; St. Petersburg State Pediatric Medical University
2 shared publications A. L. Muravtseva
Petrov National Medical Research Center for Oncology
1 shared publication
Latest Publications
- Open Access
- 24 August 2025
- Published by Russian Society of Clinical Oncology in Malignant tumours
- Vol. 15 (2) , 66-72
Russian consensus on prevention, diagnosis and treatment of gastric cancer. Questions of instrumental diagnostics
Российский консенсус по профилактике, диагностике и лечению рака желудка. Вопросы инструментальной диагностики
- 24 August 2025
- Published by Russian Society of Clinical Oncology in Malignant tumours
- Vol. 15 (2) , 66-72
Open AccessRussian consensus on prevention, diagnosis and treatment of gastric cancer. Questions of instrumental diagnostics
Российский консенсус по профилактике, диагностике и лечению рака желудка. Вопросы инструментальной диагностики
- 1 January 2022
- Published by Northwestern District Scientific and Clinical Center named after L.G. Sokolova in The Hospital
- No. 2,p. 55-67
RADIATION METHODS FOR DIAGNOSING AND STAGING GASTRIC CANCER: WHAT IS IMPORTANT FOR A SURGEON TO KNOW
По данным Международного агентства по изучению рака (International Agency for Research on Cancer, IARC) за 2020 год, рак желудка (РЖ) занимает пятое место в структуре онкологической заболеваемости и третье место в структуре смертности от онкологических заболеваний в мире [1]. Высокий уровень смертности и неудовлетворительные результаты лечения РЖ связаны не только с его поздней диагностикой [2], но и с неправильным стадированием на дооперационном этапе, что влечет за собой выбор неверной тактики лечения [3]. Хирургический метод остается основным в обеспечении радикальности лечения РЖ [4], а системная противоопухолевая терапия способствует улучшению прогноза резектабельных пациентов с местнораспространенными формами заболевания [5]. Основными факторами, влияющими на прогноз заболевания, является стадия опухолевого процесса и радикальность оперативного вмешательства [6]. Обеспечение абластики может быть достигнуто дооперационным планированием объема оперативного вмешательства для уменьшения развития локорегиональных рецидивов и улучшения общей выживаемости [7, 8]. Наиболее важным аспектом стадирования с последующим выбором оптимального подхода к лечению конкретного пациента является качественная и достоверная визуализация, в том числе с использованием лучевых методов диагностики [9, 10]. В статье мы рассматриваем особенности визуализации и возможности таких высокотехнологичных методов лучевой диагностики, как: традиционная рентгеноскопия и рентгенография, компьютерная томография (КТ), магнитно-резонансная томография (МРТ), методики ядерной медицины (ПЭТ) в диагностике и стадировании рака желудка, опираясь на данные литературы и наш собственный опыт, полученный в ФГБУ «Национальный медицинский исследовательский центр онкологии имени Н. Н. Петрова» Минздрава...
- 1 January 2022
- Published by Northwestern District Scientific and Clinical Center named after L.G. Sokolova in The Hospital
- No. 2,p. 55-67
RADIATION METHODS FOR DIAGNOSING AND STAGING GASTRIC CANCER: WHAT IS IMPORTANT FOR A SURGEON TO KNOW
По данным Международного агентства по изучению рака (International Agency for Research on Cancer, IARC) за 2020 год, рак желудка (РЖ) занимает пятое место в структуре онкологической заболеваемости и третье место в структуре смертности от онкологических заболеваний в мире [1]. Высокий уровень смертности и неудовлетворительные результаты лечения РЖ связаны не только с его поздней диагностикой [2], но и с неправильным стадированием на дооперационном этапе, что влечет за собой выбор неверной тактики лечения [3]. Хирургический метод остается основным в обеспечении радикальности лечения РЖ [4], а системная противоопухолевая терапия способствует улучшению прогноза резектабельных пациентов с местнораспространенными формами заболевания [5]. Основными факторами, влияющими на прогноз заболевания, является стадия опухолевого процесса и радикальность оперативного вмешательства [6]. Обеспечение абластики может быть достигнуто дооперационным планированием объема оперативного вмешательства для уменьшения развития локорегиональных рецидивов и улучшения общей выживаемости [7, 8]. Наиболее важным аспектом стадирования с последующим выбором оптимального подхода к лечению конкретного пациента является качественная и достоверная визуализация, в том числе с использованием лучевых методов диагностики [9, 10]. В статье мы рассматриваем особенности визуализации и возможности таких высокотехнологичных методов лучевой диагностики, как: традиционная рентгеноскопия и рентгенография, компьютерная томография (КТ), магнитно-резонансная томография (МРТ), методики ядерной медицины (ПЭТ) в диагностике и стадировании рака желудка, опираясь на данные литературы и наш собственный опыт, полученный в ФГБУ «Национальный медицинский исследовательский центр онкологии имени Н. Н. Петрова» Минздрава...
- Open Access
- 31 October 2021
- Published by Tomsk Cancer Research Institute in Siberian journal of oncology
- Vol. 20 (5) , 18-30
ROLE OF COMPUTED TOMOGRAPHY WITH PNEUMOGASTROGRAPHY IN DETERMINING THE REGRESSION GRADE OF LOCALLY ADVANCED GASTRIC CANCER AFTER NEOADJUVANT CHEMOTHERAPY
Introduction. A multimodal approach to the treatment of locally advanced gastric cancer with the addition of systemic or local treatment methods, such as chemotherapy and radiation therapy, reduces the risk of cancer recurrence, thus improving survival of patients. Advances in anticancer therapy dictate the need to develop systems for assessing tumor response to new treatment modalities.Material and Methods. The study included 162 patients with locally advanced gastric cancer who received treatment at the N.N. Petrov National Medical Research Center of Oncology from 2015 to 2018. All patients underwent subtotal gastric resection or gastrectomy with lymph node dissection and previously received neoadjuvant polychemotherapy. Patients were in the age range 30 to 80 years old. The tumor pathomorphological response to chemotherapy was assessed in all patients using a pathomorphological response rate system according to the classification of the Japanese Gastric Cancer Association (JGCA, 3rd English edition). All patients underwent computed tomography with pneumogastrography before neoadjuvant chemotherapy and immediately before surgery. For each of 162 patients, 96 qualitative and quantitative biomarkers of tumor and paragastric lymph node imaging were analyzed.Results. The accuracy of determining the tumor response rate using computed tomography with pneumogastrography was 82.6 % for TRG-0/1, 90 % for TRG-1/2, and 88 % for TRG-2/3. Discussion. The tumor pathomorphological response to treatment is a predictor of long-term results; however, it can be assessed only after analyzing the surgical specimen, and this marker cannot be used in inoperable cases and for correction of palliative chemotherapy. The study of imaging biomarkers based on quantitative and qualitative data reflecting the histopathological features of the tumor and lymph nodes can help determine the tumor regression grade and optimize treatment.Conclusion. The proposed algorithm for assessing the response grade of locally advanced gastric cancer to chemotherapy using imaging biomarkers is a promising prognostic marker and requires further study.
- 31 October 2021
- Published by Tomsk Cancer Research Institute in Siberian journal of oncology
- Vol. 20 (5) , 18-30
Open AccessROLE OF COMPUTED TOMOGRAPHY WITH PNEUMOGASTROGRAPHY IN DETERMINING THE REGRESSION GRADE OF LOCALLY ADVANCED GASTRIC CANCER AFTER NEOADJUVANT CHEMOTHERAPY
Introduction. A multimodal approach to the treatment of locally advanced gastric cancer with the addition of systemic or local treatment methods, such as chemotherapy and radiation therapy, reduces the risk of cancer recurrence, thus improving survival of patients. Advances in anticancer therapy dictate the need to develop systems for assessing tumor response to new treatment modalities.Material and Methods. The study included 162 patients with locally advanced gastric cancer who received treatment at the N.N. Petrov National Medical Research Center of Oncology from 2015 to 2018. All patients underwent subtotal gastric resection or gastrectomy with lymph node dissection and previously received neoadjuvant polychemotherapy. Patients were in the age range 30 to 80 years old. The tumor pathomorphological response to chemotherapy was assessed in all patients using a pathomorphological response rate system according to the classification of the Japanese Gastric Cancer Association (JGCA, 3rd English edition). All patients underwent computed tomography with pneumogastrography before neoadjuvant chemotherapy and immediately before surgery. For each of 162 patients, 96 qualitative and quantitative biomarkers of tumor and paragastric lymph node imaging were analyzed.Results. The accuracy of determining the tumor response rate using computed tomography with pneumogastrography was 82.6 % for TRG-0/1, 90 % for TRG-1/2, and 88 % for TRG-2/3. Discussion. The tumor pathomorphological response to treatment is a predictor of long-term results; however, it can be assessed only after analyzing the surgical specimen, and this marker cannot be used in inoperable cases and for correction of palliative chemotherapy. The study of imaging biomarkers based on quantitative and qualitative data reflecting the histopathological features of the tumor and lymph nodes can help determine the tumor regression grade and optimize treatment.Conclusion. The proposed algorithm for assessing the response grade of locally advanced gastric cancer to chemotherapy using imaging biomarkers is a promising prognostic marker and requires further study.
- Open Access
- 23 July 2021
- Published by Luchevaya Diagnostika in Journal of radiology and nuclear medicine
- Vol. 102 (3) , 155-165
Gastric Cancer Imaging: Computed Tomographic Pneumogastrography
Objective: to reveal technical nuances for obtaining high-quality images using a computed tomography protocol with pneumogastrography and virtual gastroscopy, which contribute to the detection and assessment of the morphological type of gastric cancer and to the determination of its localization and invasion depth.Material and methods. The investigation enrolled 250 patients with both early (24.8%) and locally advanced (75.2%) gastric cancer treated in Petrov National Medical Research Center for Oncology from 2015 to 2018. Preoperative chemotherapy was performed in 142 (56.8%) patients and was not done in 108 (43.2%). All the patients underwent preoperative computed tomography with pneumogastrography and virtual gastroscopy. All the patients were radically operated on through subtotal or total gastric resection.Results. Computed tomography with pneumogastrography and virtual gastroscopy was used to detect gastric cancer in 98.4% of patients; the cases with early T1a and T1b invasion depth cancers were 23.2%. The tumor could not be significantly differentiated in 4 (1.6%) patients. This group consisted of: 3 (1.2%) and 1 (0.4%) patients with pT1a and pT1b invasion depth tumors, respectively. All non-visualized tumors had a superficial morphological type of growth (Type 0–II (3 cases with 0–IIa and 1 case with 0–IIb); their sizes were less than 2 cm. Three tumors were localized in the antral portion of the stomach; one was in its cardiac portion.Conclusion. Computed tomography with pneumogastrography and virtual gastroscopy is an effective technique to detect gastric cancer, including its early types of category T1, which makes it possible to assess its localization, morphological type, and invasion depth.
- 23 July 2021
- Published by Luchevaya Diagnostika in Journal of radiology and nuclear medicine
- Vol. 102 (3) , 155-165
Open AccessGastric Cancer Imaging: Computed Tomographic Pneumogastrography
Objective: to reveal technical nuances for obtaining high-quality images using a computed tomography protocol with pneumogastrography and virtual gastroscopy, which contribute to the detection and assessment of the morphological type of gastric cancer and to the determination of its localization and invasion depth.Material and methods. The investigation enrolled 250 patients with both early (24.8%) and locally advanced (75.2%) gastric cancer treated in Petrov National Medical Research Center for Oncology from 2015 to 2018. Preoperative chemotherapy was performed in 142 (56.8%) patients and was not done in 108 (43.2%). All the patients underwent preoperative computed tomography with pneumogastrography and virtual gastroscopy. All the patients were radically operated on through subtotal or total gastric resection.Results. Computed tomography with pneumogastrography and virtual gastroscopy was used to detect gastric cancer in 98.4% of patients; the cases with early T1a and T1b invasion depth cancers were 23.2%. The tumor could not be significantly differentiated in 4 (1.6%) patients. This group consisted of: 3 (1.2%) and 1 (0.4%) patients with pT1a and pT1b invasion depth tumors, respectively. All non-visualized tumors had a superficial morphological type of growth (Type 0–II (3 cases with 0–IIa and 1 case with 0–IIb); their sizes were less than 2 cm. Three tumors were localized in the antral portion of the stomach; one was in its cardiac portion.Conclusion. Computed tomography with pneumogastrography and virtual gastroscopy is an effective technique to detect gastric cancer, including its early types of category T1, which makes it possible to assess its localization, morphological type, and invasion depth.
- Open Access
- 15 June 2021
- Published by ECO-Vector LLC in Bulletin of the Russian Military Medical Academy
- Vol. 23 (2) , 99-106
Diagnosis and t-staging of gastric cancer: comparison of standard computed tomography and computed-tomographic pneumogastrography
The advantages of computed tomographic pneumogastrography with the possibility of three-dimensional visualization and virtual gastroscopy in diagnosing gastric cancer are considered. The study included 479 patients with histologically diagnosed gastric cancer who were treated at the National Medical Research Center of Oncology named after N.N. Petrov from 2011 to 2018. 232 patients received preoperative chemotherapy. All patients underwent surgery: 70 in the volume of endoscopic dissection, 40 proximal subtotal resection, 166 distal subtotal resection, 203 gastrectomy. All patients at the preoperative stage underwent staging computed tomography on a 64-slice X-ray computed tomograph: 208 patients underwent computed tomography according to the standard protocol without targeted preparation of the stomach for the study, 271 patients with targeted preparation of the stomach for the study according to the computed tomographic pneumogastrography protocol. The sensitivity of the computed tomography in assessing the T-stage was assessed by comparison with pathomorphological data. Of the 208 patients who underwent computed tomography according to the standard protocol, a gastric cancer was detected in 111 (53.4%), out of 271 patients who underwent computed tomography pneumogastrography, a gastric cancer was detected in 267 (98.52%), which is a statistically significant difference in comparing computed tomography methods (Pearson, 144.223, df = 1; p 0.001). There are statistically significant differences when comparing computed tomography according to the standard protocol and computed tomographic pneumogastrography in detecting gastric cancer for all tumor categories: T/yT1 8.2 and 94.4% (Pearson, 99.205, df = 1; p 0.001), T/yT2 47.8 and 100% (Pearson, 24.681, df = 1; p 0.001), T/yT3 72.3 and 100% (Pearson, 33.114, df = 1; p 0.001), T/yT4 90.0 and 100% (Pearson, 4.789, df = 1; p = 0.029) respectively. There are also statistically significant differences when comparing the sensitivity of computed tomography according to the standard protocol and computed tomographic pneumogastrography in determining tumor invasion for all tumor categories: T/yT1 0 and 69.4% (Pearson, 67.880, df = 1; p 0.001), T/yT2 26.1 and 71.1% (Pearson, 11.666, df = 1; p 0.001), T/yT3 32.9 and 84.6% (Pearson, 54.900, df = 1; p 0.001), T/yT4 73.3 and 95.7% (Pearson, 7.916, df = 1; p = 0.005) respectively. In general, the sensitivity of the computed tomography according to the standard protocol for determining the T-stage of gastric cancer was 28.4%, computed tomographic pneumogastrography 77.1% (Pearson, 113.505, df = 1; p 0.001). Computed tomographic pneumogastrography with the possibility of three-dimensional visualization and virtual gastroscopy significantly increases the indicators of the effectiveness of diagnosing gastric cancer both early forms (category T1) and with deeper invasion (categories T2T4), demonstrates high sensitivity in determining T/yT-stages.
- 15 June 2021
- Published by ECO-Vector LLC in Bulletin of the Russian Military Medical Academy
- Vol. 23 (2) , 99-106
Open AccessDiagnosis and t-staging of gastric cancer: comparison of standard computed tomography and computed-tomographic pneumogastrography
The advantages of computed tomographic pneumogastrography with the possibility of three-dimensional visualization and virtual gastroscopy in diagnosing gastric cancer are considered. The study included 479 patients with histologically diagnosed gastric cancer who were treated at the National Medical Research Center of Oncology named after N.N. Petrov from 2011 to 2018. 232 patients received preoperative chemotherapy. All patients underwent surgery: 70 in the volume of endoscopic dissection, 40 proximal subtotal resection, 166 distal subtotal resection, 203 gastrectomy. All patients at the preoperative stage underwent staging computed tomography on a 64-slice X-ray computed tomograph: 208 patients underwent computed tomography according to the standard protocol without targeted preparation of the stomach for the study, 271 patients with targeted preparation of the stomach for the study according to the computed tomographic pneumogastrography protocol. The sensitivity of the computed tomography in assessing the T-stage was assessed by comparison with pathomorphological data. Of the 208 patients who underwent computed tomography according to the standard protocol, a gastric cancer was detected in 111 (53.4%), out of 271 patients who underwent computed tomography pneumogastrography, a gastric cancer was detected in 267 (98.52%), which is a statistically significant difference in comparing computed tomography methods (Pearson, 144.223, df = 1; p 0.001). There are statistically significant differences when comparing computed tomography according to the standard protocol and computed tomographic pneumogastrography in detecting gastric cancer for all tumor categories: T/yT1 8.2 and 94.4% (Pearson, 99.205, df = 1; p 0.001), T/yT2 47.8 and 100% (Pearson, 24.681, df = 1; p 0.001), T/yT3 72.3 and 100% (Pearson, 33.114, df = 1; p 0.001), T/yT4 90.0 and 100% (Pearson, 4.789, df = 1; p = 0.029) respectively. There are also statistically significant differences when comparing the sensitivity of computed tomography according to the standard protocol and computed tomographic pneumogastrography in determining tumor invasion for all tumor categories: T/yT1 0 and 69.4% (Pearson, 67.880, df = 1; p 0.001), T/yT2 26.1 and 71.1% (Pearson, 11.666, df = 1; p 0.001), T/yT3 32.9 and 84.6% (Pearson, 54.900, df = 1; p 0.001), T/yT4 73.3 and 95.7% (Pearson, 7.916, df = 1; p = 0.005) respectively. In general, the sensitivity of the computed tomography according to the standard protocol for determining the T-stage of gastric cancer was 28.4%, computed tomographic pneumogastrography 77.1% (Pearson, 113.505, df = 1; p 0.001). Computed tomographic pneumogastrography with the possibility of three-dimensional visualization and virtual gastroscopy significantly increases the indicators of the effectiveness of diagnosing gastric cancer both early forms (category T1) and with deeper invasion (categories T2T4), demonstrates high sensitivity in determining T/yT-stages.